Eli Lilly Stocks Rise as China Approves Orforglipron Weight-Loss Pill
Lilly's oral obesity drug wins Chinese approval, setting up a fight with Novo Nordisk, Pfizer and Innovent in a vast market.

What's Your Reaction?









